Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NVrjZ4VkTnWwY4Tpc44hSXO|YYm= M3HYWFAvOS1|MDFOwG0> NWnWeZdMPDhiaB?= Mlj5bY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> NEjmTYYzPjVzM{G3Ni=>
H460 NY\DZmNxTnWwY4Tpc44hSXO|YYm= MWCwMlEuOzBizszN MmTkOFghcA>? NHe5OZlqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? MV[yOlUyOzF5Mh?=
HKESC-2 NX\QNmxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSyNOKh|ryP NWjDdZl4PDkEoHlCpC=> Mo\sd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh NHvnNYEzPjR5NE[5Ny=>
CaES-17 M1WxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLJNlDDqM7:TR?= MVm0POKhcMLi NUjqV41He2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi Ml3HNlY1PzR4OUO=
HKESC-2 NYTYUWxPSXCxcITvd4l{KEG|c3H5 NIPNWo0zOMLizszN MnfYOFjDqGkEoB?= MUPy[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz MXWyOlQ4PDZ7Mx?=
CaES-17 NV3mSpV1SXCxcITvd4l{KEG|c3H5 Mkn3NlDDqM7:TR?= MXS0POKhcMLi M1PjXpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NVnQS2ViOjZ2N{S2PVM>
A549 NG\TZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTBcYo2NTF4MDFOwG0> MVy0POKhcMLi NEXJUJJFVVOR NF;keIJKSzVyPUG2N{41KM7:TR?= Mmn0NlY1PjR4NEO=
HCC827 NXnqV|QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\6OU0yPjBizszN M1z1VFQ5yqCqwrC= M3PjbWROW09? NFHVZ3NKSzVyPU[5MlIh|ryP M3znPVI3PDZ2NkSz
A549 MXzBdI9xfG:|aYOgRZN{[Xl? MmT6PFAhyrWP MorkOFjDqGkEoB?= Mn70SG1UVw>? MkjpbY5lfWOnczDhdI9xfG:|aYO= NEO3ZZczPjR4NE[0Ny=>
HCC827 MYDBdI9xfG:|aYOgRZN{[Xl? Mn3MPFAhyrWP M4nI[VQ5yqCqwrC= MlXXSG1UVw>? NF\rWVBqdmS3Y3XzJIFxd3C2b4Ppdy=> MViyOlQ3PDZ2Mx?=
SGC-7901/DDP M1f6cGZ2dmO2aX;uJGF{e2G7 NYOzNIcyOTEEoNM1US=> NInOXVczPCCq NWjUc3J{cW6qaXLpeJMh[3mlbH;vfJlo\W6jc3WtNkBidmRiUD3ncJlkd3C{b4TlbY4h\XiycnXzd4lwdg>? NWrnR2RWOjZ2MEe2OVM>
SGC-7901  Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLFNlTDqGkEoB?= NIm3TYhKSzVyPUGxOU4xQCEQvF2= MUGyOlQxPzZ3Mx?=
SGC-7901/DDP MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuyOOKhcMLi NX3WUGZEUUN3ME2zOU41PSEQvF2= M1vReVI3PDB5NkWz
SGC-7901/DDP NHfDR4xCeG:ydH;zbZMhSXO|YYm= M1vXN|ExyqEEtV2= NV[0OmQ2OjRiaB?= MXHpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKHerdHigZ4l{eGyjdHnu NFTVR4UzPjRyN{[1Ny=>
SGC-7901/DDP MonhSpVv[3Srb36gRZN{[Xl? M2PzbVExyqEEtV2= M4rFXFI1KGh? MnXQbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB? NYDQVYVjOjZ2MEe2OVM>
SGC-7901/DDP M3HzbWZ2dmO2aX;uJGF{e2G7 MorhNVDDqML3TR?= NUjQbFh7OjRiaB?= NVnaN4NM[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv NXy3WGFLOjZ2MEe2OVM>
H357 NV;VcmVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELJTZI4NjVxMUCg{txO NGfJTG81QCCq M2Oz[GROW09? M1HIWYlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg> NEXtOHQzPjByOUi3OC=>
TAF MWPGeY5kfGmxbjDBd5NigQ>? NVLuenV1OTEEoNM1US=> MWq3JIQ> MWjh[oZm[3S|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>? NX7QcnNSOjV7OEexNlc>
TAF NWj2[VdYTnWwY4Tpc44hSXO|YYm= M4DFWFExyqEEtV2= MWKzNE0yOjBibXnu MXPwc49zdHliYX\m[YN1eyCmQXv0JJBpd3OyaH;yfYxifGmxbjDjc45{\XG3ZX70JJRwKEWJRjDzbYdv[Wyrbne= NEXseGozPTl6N{GyOy=>
TAF NYDUc|g1TnWwY4Tpc44hSXO|YYm= MYmxNOKhyrWP MnzlOFghcA>? NGHpOIRqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M1PYdVI2QTh5MUK3
PANC-1 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjGNlAwPjBxMUCwJO69VQ>? M1K5[VI1NzR6L{eyJIg> Ml;DbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVSyOVk4OzB4Mh?=
PANC-1 MYTGeY5kfGmxbjDBd5NigQ>? M{PCWVIxNzZyL{GwNEDPxE1? MkG1NlQhcA>? NXj2XYh[[XS2ZX71ZZR{KGOnbHygbY53[XOrb36gZY5lKG2rZ4LheIlwdiCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NYHFfXY6OjV7N{OwOlI>
HeLa  NUm0R4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TUb|IxyqEQvF5CpC=> NYXNVJNtOjUEoHi= NX\lSHRK\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NEPNRmozPTd5MESyNy=>
SACC-83 NYG3S|RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6yNOKh|ryPwrC= MXOyOOKhcA>? NWnYd3VU\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= M3XNVFI2PzdyNEKz
HeLa  M2TQXmFxd3C2b4Ppd{BCe3OjeR?= NUnDSYZqOjEEoN88UeKh NW\PfGZOOjUEoHi= M4TFdIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> M1;6VVI2PzdyNEKz
SACC-83 Mly1RZBweHSxc3nzJGF{e2G7 NWLwPYFCOjEEoN88UeKh Mnz6NlTDqGh? MXHlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz M2jMSVI2PzdyNEKz
HeLa  M2jQU2Z2dmO2aX;uJGF{e2G7 M4jHWVIxNzRyL{iwJO69VQ>? NF24bWEzPMLiaB?= NXvzUm1LfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? NGTqV|AzPTd5MESyNy=>
SACC-83 NV;pUFdvTnWwY4Tpc44hSXO|YYm= NYm0NmNnOjBxNECvPFAh|ryP MXuyOOKhcA>? MYX1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> MnH4NlU4PzB2MkO=
HLCZ01 M2O4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS3R|hiOOLCk{[wxsDDvU1? NW\seoEzPDhiaB?= NEjWVmNFVVOR M1\QcYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MmruNlU4OjR6OUm=
HLCZ01 NImxZnRHfW6ldHnvckBCe3OjeR?= MkHjOFDDqM7:TR?= MofRNlQhcA>? MX7EUXNQ M3LIVYlv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> M4PIXlI2PzJ2OEm5
HLCZ01 MmD5RZBweHSxc3nzJGF{e2G7 MlXMOFDDqM7:TR?= M3PLdFI1KGh? NITGV2RFVVOR NXj1[nNw\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z NXL3TJl7OjV5MkS4PVk>
HLCZ01 M{ixWmZ2dmO2aX;uJGF{e2G7 MVK0NOKh|ryP NGq4UnczPCCq NFHHSnVFVVOR NXvQeHNtcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y NUTMb|I{OjV5MkS4PVk>
MGC803 NXLJSpFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjvPW0xNTZyIN88US=> NGL2[ZM4OiCq NYD5dZQxUUN3ME20O{4zPeLCidMx5qCKPi52MzFOwG0> NXHJe4lCOjV5MEGzO|g>
SGC7901 M2rDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7KcGoxNTZyIN88US=> NUfYOI1xPzJiaB?= NV[2[5ZPUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> NETue40zPTdyMUO3PC=>
MGC803 MnS0SpVv[3Srb36gRZN{[Xl? NEXmSos1OMLizszN MWW4M|E3NzJ2IHi= MoLpeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u MlXsNlU4ODF|N{i=
SGC7901 NWOyXpgxTnWwY4Tpc44hSXO|YYm= M17pWVQxyqEQvF2= MUG4M|E3NzJ2IHi= MlK0eZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u NUPaSIpQOjV5MEGzO|g>
MCF-7  NGKwTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zNU8yOCEQvF2= MUm3NkBp NF7lN21FVVOR MmTy[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NYfFZXZiOjV4Nke1NVA>
MDA-MB-231  NFXOOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexM|ExKM7:TR?= NEW1SXA4OiCq NV;2XJQ6TE2VTx?= NFy1XWFmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= NE\COY0zPTZ4N{WxNC=>
MDA-MB-231 NU\MPGh1TnWwY4Tpc44hSXO|YYm= NXHJV2JnOC12MDFCuW0> MknBOE0zPCCq M3\E[olv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NGe4XmYzPTV6N{OyPS=>
MCF-7 MYLGeY5kfGmxbjDBd5NigQ>? NFLFZYQxNTRyINM1US=> MmnYOE0zPCCq Mlzu[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? M1\ERVI2PTh5M{K5
MCF7-MX  Mk\CSpVv[3Srb36gRZN{[Xl? M2TWdlAuPDBiwsXN MV:0MVI1KGh? M4rNeIVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? NX7WN5hMOjV3OEezNlk>
MDA-MB-231 M3XEfGZ2dmO2aX;uJGF{e2G7 NHW5WYExNTRyINM1US=> NGDHbWY1NTJ2IHi= NVzl[Ipie3SrbYXsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCDQlPHNkB2eCC2bzC0MlI4KHSrbXXzJJRwKGOxboTyc4whdGW4ZXygZpkhOTJiaNMg NUTPR4gyOjV3OEezNlk>
A2780 M3jjOmZ2dmO2aX;uJGF{e2G7 MmrTOU8yOC9zNTFOwG0> NHnrNYE1QCCq MV7k[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHezfmczPTR{NEi5PC=>
SKOV3  NUfCbIxXTnWwY4Tpc44hSXO|YYm= MV:1M|ExNzF3IN88US=> NVXJfFM6PDhiaB?= MXjk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVrGe2hSOjV2MkS4PVg>
A2780 M{jBTmZ2dmO2aX;uJGF{e2G7 M2GwT|UwOTBxMUWg{txO NXP3bJRyPDhiaB?= Ml25[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? NYm4OIZQOjV2MkS4PVg>
SKOV3  NUi2ZVRGTnWwY4Tpc44hSXO|YYm= MXe1M|ExNzF3IN88US=> MnPYOFghcA>? Ml7H[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? NInGboMzPTR{NEi5PC=>
A2780 M3Ha[WZ2dmO2aX;uJGF{e2G7 MYi1M|ExNzF3IN88US=> NGL3eFg1QCCq NWrXV2s4\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu NH3HfnczPTR{NEi5PC=>
SKOV3  NWnJOlJiTnWwY4Tpc44hSXO|YYm= M4C5OlUwOTBxMUWg{txO M2\ne|Q5KGh? NHvu[pdl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= NGrkOpEzPTR{NEi5PC=>
A2780 NIXXZ49HfW6ldHnvckBCe3OjeR?= M{DYVVUwOTBxMUWg{txO NHyw[XgyKGh? NUXtRpNQcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQVvUJIFv\CCyLVXST{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXmyOVQzPDh7OB?=
SKOV3  M{f4T2Z2dmO2aX;uJGF{e2G7 NVm3eIREPS9zMD:xOUDPxE1? MX2xJIg> NUHTSnJ4cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQVvUJIFv\CCyLVXST{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYTIfm5oOjV2MkS4PVg>
HCT-15 M{TrWWZ2dmO2aX;uJGF{e2G7 MUexNE02OCEQvF2= MmPWOk0{PiCq MWjpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NWTwUGFuOjV{MUiwNlg>
HT-29  NH7xc4lHfW6ldHnvckBCe3OjeR?= NHzsN3QyOC13MDFOwG0> MnruOk0{PiCq NGPTbXpqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MX2yOVIyQDB{OB?=
HSC3  MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MofGNQKBmzRyIN88US=> MlHEOFghcA>? M4PRT2lEPTB;MkWuOeKyOS55OECg{txO NFuwdGgzPTF7OEe4PS=>
HSC3  M4DwW2Fxd3C2b4Ppd{BCe3OjeR?= M3\uXVI2KM7:TR?= NXXTcI5QPDhiaB?= MorJbY5lfWOnczDhdI9xfG:|aYO= M2juVVI2OTl6N{i5
HSC3  Ml7vSpVv[3Srb36gRZN{[Xl? MWeyOUDPxE1? MkDiOFghcA>? MYLlfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV MXGyOVE6QDd6OR?=
HSC3  NInoVXpHfW6ldHnvckBCe3OjeR?= NU\VdVZOOjVizszN MkfsOFghcA>? MUjpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= NUfOPXdoOjVzOUi3PFk>
HSC3  Ml;SSpVv[3Srb36gRZN{[Xl? NFX6WZczPSEQvF2= NXjqRlNLPzJiaB?= NXvNOpZX\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh NVXRU2lSOjVzOUi3PFk>
201T  NIfhdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LyVVczKGh? MVvEUXNQ MXjJR|UxRTR6Lk[gxtVO M{PnNlI2ODV5OUSx
273T MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK3NkBp Ml\BSG1UVw>? NUHv[YE5UUN3ME24NE42KML3TR?= NEjkOWwzPTB3N{m0NS=>
Hep-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHTN|AwPTBxMUCwJO69VQ>? MXWxNk8zPC9|Nj:0PEBp MnTHSG1UVw>? M3\PfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{HrXVI1QTl6NU[0
Hep-2 NETmcIdCeG:ydH;zbZMhSXO|YYm= MXu1NEDPxE1? NHHn[mIxNTR6IHi= MnzqSG1UVw>? M2nYOYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy NIPzb3EzPDl7OEW2OC=>
Hep-2 NV:xfod6TnWwY4Tpc44hSXO|YYm= NVfQRo9rPTBizszN NX;nOIlROC12ODDo Mn7FSG1UVw>? M{PodpJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 MkXSNlQ6QTh3NkS=
Hep-2 NV;0eVJTTnWwY4Tpc44hSXO|YYm= M2LpVFUxKM7:TR?= MlzZNE01QCCq NIT6RnJFVVOR NVO5ZnJP\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? Moq0NlQ6QTh3NkS=
SGC-7901 NESzRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT4NVAwPTBxMUCwJO69VQ>? MlfMNlQwPDhxN{KgbC=> NEDoWWFFVVOR MorkbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVO0WpVpOjR7OUK5OVg>
MKN-45 M2XrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\OZYQyOC93MD:xNFAh|ryP NIfqXXQzPC92OD:3NkBp MULEUXNQ M2T1[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M2DNTVI1QTl{OUW4
SGC-7901 NGjjUHpHfW6ldHnvckBCe3OjeR?= NIC1VmYyOC93MD:xNFAh|ryP MmjyOFghcA>? NHjDbHpFVVOR M2P0S4Rwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2\BTVI1QTl{OUW4
MKN-45 M2HRW2Z2dmO2aX;uJGF{e2G7 M4X0SVExNzVyL{GwNEDPxE1? M3;1OFQ5KGh? MoHhSG1UVw>? NEC0OHBld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MUWyOFk6Ojl3OB?=
C666-1 MXLDfZRwfG:6aXPpeJkhSXO|YYm= M4rzNFIxNThyIN88US=> NGGzXG4zPCCq MVfk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MYWyOFg2PDh|OB?=
CNE-1 M3[0XmN6fG:2b4jpZ4l1gSCDc4PhfS=> M{C5PFIxNThyIN88US=> NYDzcWlDOjRiaB?= NH[ybm1l\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MmPHNlQ5PTR6M{i=
CNE-2 M1jDdmN6fG:2b4jpZ4l1gSCDc4PhfS=> MWOyNE05OCEQvF2= NF6zSHUzPCCq M4\DUYRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NUP1V2U2OjR6NUS4N|g>
C666-1 M2q2[WN6fG:2b4jpZ4l1gSCDc4PhfS=> NFLNfpQ3OCEQvF2= MUO3JIQ> NX\yfmpp\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NFTEVpIzPDh3NEizPC=>
CNE-1 M{LqS2N6fG:2b4jpZ4l1gSCDc4PhfS=> MYK2NEDPxE1? NXXLUpY4PyCm NEnXfnVmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> NH7lSZAzPDh3NEizPC=>
SNU-1041 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULvRodnOC12MDFOwG0> M3X6SVQ5KGh? NU\xVJFscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M{TjZVI1Pjl{N{Cz
SNU-1041 MYLGeY5kfGmxbjDBd5NigQ>? MWiyNE8{OCEQvF2= NWj5c4hWPCCq MlnWbY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> NYDZSVdDOjR4OUK3NFM>
SNU-1041 NXW0bndLTnWwY4Tpc44hSXO|YYm= NXftXG1sOC12MDFOwG0> MoHrOEBp NFSzN412eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= MX6yOFY6OjdyMx?=
SGC-7901 M{PqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK1NE0yOjVizszN NGXreZkzPC92OD:3NkBp MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWHHeVJKOjR4N{[zPVQ>
SGC-7901 M3vjbmFxd3C2b4Ppd{BCe3OjeR?= M2TnUFExOCEQvF2= M1Pxd|czKGh? NEHpXmNqdmS3Y3XzJIFxd3C2b4Ppdy=> NVX0RoZ2OjR4N{[zPVQ>
SGC-7901 NGi4cHFHfW6ldHnvckBCe3OjeR?= MlznO|UwOTByL{GyOUDPxE1? MUmyOE81QC95MjDo M3nPOolv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy MU[yOFY4PjN7NB?=
LMeC  Ml;RSpVv[3Srb36gRZN{[Xl? MX[yNE82OCEQvF2= MmW1OFghcA>? M4rzfIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw MXKyOFY2Pjd2Nh?=
CMeC-1 NXPQPJdUS2WubDDWbYFjcWyrdImgRZN{[Xl? MWmyNE82OCEQvF2= Ml3yOFghcA>? NGHPZ5FqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NWTUbm11OjR4NU[3OFY>
LMeC MUHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnLrNlAwPTBizszN M1PaNVQ5KGh? NFm1cZVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{PIOFI1PjV4N{S2
CMeC-1 M3XoR2Z2dmO2aX;uJGF{e2G7 MmjKNlAwPTBizszN MVS0PEBp M37TTYlv\HWlZYOgS|EuWyCjcoLld5Q> NULpZWJQOjR4NU[3OFY>
LMeC M37sZWZ2dmO2aX;uJGF{e2G7 MlnxNlAwPTBizszN MXi0PEBp M3HCWIlv\HWlZYOgS|EuWyCjcoLld5Q> NFTsdGQzPDZ3Nke0Oi=>
CMeC-1 MkLpSpVv[3Srb36gRZN{[Xl? MVOyNE82OCEQvF2= NUP0OXlmPDhiaB?= NXWycWJO\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NF\WdmczPDZ3Nke0Oi=>
LMeC NUXi[nJrTnWwY4Tpc44hSXO|YYm= NYC4OY45OjBxNUCg{txO NGLoXYI1QCCq NHTJe3pl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYfIdlZUOjR4NU[3OFY>
CMeC-1 NI\VdYpHfW6ldHnvckBCe3OjeR?= NXLzW2xlOjBxNUCg{txO M1nuZVQ5KGh? MULpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u M17acFI1PjV4N{S2
LMeC MVjGeY5kfGmxbjDBd5NigQ>? NYjuelVYOjBxNUCg{txO M4rtW|Q5KGh? MonObY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MV[yOFY2Pjd2Nh?=
OVCAR-3 MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX[xNEDDvU1? NVTRTXAyOSCq Mn\z[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> NVGzb2xSOjR3MkCyNlc>
OVCAR-3 MUfBdI9xfG:|aYOgRZN{[Xl? M1PQUFExKML3TR?= NIXmWHAyKGh? M4iyWZBzd22xdHXzJJBi[2yrdHH4[YwucW6mdXPl[EBieG:ydH;zbZPDqA>? NXG3PVhGOjR3MkCyNlc>
OVCAR-3 M3TXW2Z2dmO2aX;uJGF{e2G7 NWrMZo9POTBiwsXN MmrMNUBp NWLkO2h7\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> MXWyOFUzODJ{Nx?=
OVCAR-3 MVHGeY5kfGmxbjDBd5NigQ>? M1fvOFExKML3TR?= M{G4TFEhcA>? NWWyXGtK\G:5bj3y[Yd2dGG2ZYOgUmYu|rqEIHHjeIl3[XSrb36gbY5lfWOnZDDifUBx[WOuaYThfIVt MUSyOFUzODJ{Nx?=
OVCAR-3 NWi2OYc{TnWwY4Tpc44hSXO|YYm= NYL4[JNIOTBiwsXN MlHuNUBp M{\iNYlvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v MkDHNlQ2OjB{Mke=
CF33 NGTLU5ZHfW6ldHnvckBCe3OjeR?= MVuxNFAh|ryP M2\qVVI1KGh? MleybY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDDU3guOiCycn;0[YlvKGW6cILld5Nqd25? NGOyO2kzPDVyM{e4Ni=>
CF33 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T3Z|ExNTFyMDFOwG0> M4rGNlAuPCCm M{XSXYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2XCSFI1PTB|N{iy
CF33 NHnXb3BHfW6ldHnvckBCe3OjeR?= MUGxNE0yODBizszN Mn;XOE0zPCCq NVHRZVFS\GWlcnXhd4V{KGOnbHzzJIlvKHSqZTDTJJBp[XOnIHHu[EBqdmO{ZXHz[ZMh[2WubIOgbY4hTzBxR{GgZZJz\XO2 NEOwcIgzPDVyM{e4Ni=>
LNCaP NFy5VmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHYXnAzNzVxMUCg{txO Ml;RPVYhcA>? NFXZO3ZqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu NGHkR|YzPDJ7Nkm3PC=>
LNCaP M2\xTGFxd3C2b4Ppd{BCe3OjeR?= NYLTT5hROi93L{GwJO69VQ>? MofFPVYhcA>? NIO5[pVqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NGPpTIgzPDJ7Nkm3PC=>
PC-3  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOwMVUxKM7:TR?= MnjQOFjjiImq NHPKem5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3nEO|I1OTJ5OEiy
PC-3  M1qzT2NmdGxiVnnhZoltcXS7IFHzd4F6 M2nROlAuOTByIN88US=> M3;qbFczKGh? NGjJ[nJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MXuyOFEzPzh6Mh?=

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID